In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two ...

I am recommending a COVID booster this spring for my highest-risk patients — those with immune system diseases and older ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

RSV infects the lungs, causing pneumonia or bronchiolitis. While most children recover from RSV, it can be fatal, especially ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

The move follows Kennedy’s repeated statements about pharma-backed CDC advisory panels. The Health and Human Services ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of the virus. A booster dose one year after the initial shot failed to do ...